EMEA recommends Teva organ rejection drugs - report
The drugs are generic version's of Roche's CellCept.
The two medicines are generic versions of Roche Holding AG's (SWX: ROG) original drug CellCept, which the EMEA approved in 1996. "Reuters" noted that marketing recommendation by the EMEA's Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months.
Teva closed at $44.40 on Nasdaq on Friday, giving a market cap of $34 billion. The share rose 0.3% in after-hours trading, and fell 1% at the opening on the TASE today.
Published by Globes [online], Israel business news - www.globes-online.com - on December 16, 2007
© Copyright of Globes Publisher Itonut (1983) Ltd. 2007
- Tel Aviv market report
- Tel Aviv Stock Exchange
- Israeli stocks in NY
- Arbitrage gaps for dual-listed stocks
- Israeli stocks in Europe
- Israeli stocks on other markets
- Tel Aviv 25 options
- Mutual funds
- Current representative shekel rates
- Historical representative shekel rates
- Bank shekel rates
- Shekel/dollar options